Advertisement

Dopaminerg-induzierte Psychosen und Halluzinationen bei Morbus Parkinson

  • S. Bittkau
Conference paper

Zusammenfassung

Dopaminerg-induzierte Psychosen bei Parkinsonpatienten werden kontrovers diskutiert. Warum gerät ein kaum noch mobilisierbarer Patient im fortgeschrittenen Krankheitsstadium beim Auftreten einer Psychose in einen langdauernden On-Zustand, der selbst nach Absetzen der Dopaminagonisten für den Zeitraum dieses pharmakotoxischen Delirs anhält? Mit Nachlassen des Delirs wird ein solcher Patient zunehmend geordnet und parallel zunehmend unbeweglich, evtl. bis zum erneutem Erreichen des Off-Zustandes.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Fénelon G, Mahieux F, Huon R, Ziégler M (2000) Hallucinations in Parkinson’s disease. Brain 123: 733–745PubMedCrossRefGoogle Scholar
  2. 2.
    Goetz CG, Vogel C, Tanner CM, Stebbins GT (1998) Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 51: 811–814PubMedCrossRefGoogle Scholar
  3. 3.
    Mendis T, Barclay CL, Mohr E (1996) CNS drug-induced psychosis in Parkinson’s disease. Drugs 3: 166–174Google Scholar
  4. 4.
    Wolters EC (1999) Dopaminomimetic psychosis in Parkinson’s disease patients. Neurology 52(suppl 3): S10–S13PubMedGoogle Scholar
  5. 5.
    Ziegler B (1996) Zur Psychopathologie des Parkinson-Syndroms. Klinikarzt 9/25: 266–270Google Scholar
  6. 6.
    Melamed E, Friedberg G, Zoldan J (1999) Psychosis, Impact on the patient and family. Neurology 52(suppl 3): S14–S16PubMedGoogle Scholar
  7. 7.
    Factor SA, Molho ES, Brown DL (1998) Acute delirium after withdrawal of amantadine in Parkinson’s disease. Neurology 50: 1456–1458PubMedCrossRefGoogle Scholar
  8. 8.
    Graham JM, Grünewald RA, Sagar HJ (1997) Hallucinosis in idiopathic Parkinson’s disease. Neurology 63: 434–440Google Scholar
  9. 9.
    Inzelberg R, Kipervasser S, Korczyn AD (1998) Auditory. Neurology 64: 533–535Google Scholar
  10. 10.
    Friedman JH (1999) Intravenous levodopa in hallucinating PD patients. Neurology 52: 219–220PubMedGoogle Scholar
  11. 11.
    Makoff AJ, Graham JM, Arranz MJ, Forsyth J, Li T, Aitchison KJ, Shaikh S, Grünewald RA (2000) Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson’s disease. Pharmacogenetics 10: 43–48PubMedCrossRefGoogle Scholar
  12. 12.
    Jonnalagada JR, Norton JW (2000) Letters to the editor. Neurology 23: 230–231Google Scholar
  13. 13.
    Okada K, Suyama N, Oguro H, Yamaguchi S, Kobayashi S (1999) Medication-induced hallucination and cerebral blood flow in Parkinson’s disease. Neurology 246: 365–368CrossRefGoogle Scholar
  14. 14.
    Iansek R, Feniger H (1999) Successful psychotropic management of drug related psychosis in Parkinson’s disease. Journal of Clinical Neuroscience 6(6): 488–491PubMedCrossRefGoogle Scholar
  15. 15.
    Friedman JH, Steward A, Factor DO (2000) Atypical antipsychotics in the treatment of druginduced psychosis in Parkinson’s disease. Review. Movement Disorders 15: 201–211CrossRefGoogle Scholar
  16. 16.
    Cummings J (1999) Managing psychosis in patients with Parkinson’s disease. New Engl J Med 340: 801–803PubMedCrossRefGoogle Scholar
  17. 17.
    Millat B, Hay JM, Vallcur P, Fingerhut A, Fagniez PL, Schein M, Gecelter G (1999) Clozapine for drug-induced psychosis. New Engl J Med 341: 456Google Scholar
  18. 18.
    The Parkinson Study Group (1999) Low-dose Clozapine for the treatment of drug-induces psychosis in Parkinson’s disease. New Engl J Med 340: 757–763CrossRefGoogle Scholar
  19. 19.
    Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K (2001) Clozapine for the treatment of drug-induced psychosis in Parksinson’s disease: Results of the 12 week open label extension in the PSYCLOPS trial. The Parkinson Study Group. Movement Disorders 16: 135–139Google Scholar
  20. 20.
    Ruggieri S, De Pandis MF, Bonamartini A, Vacca L, Stocchi F (1997) Low dose of Clozapine in the treatment of dopaminergic psychosis in Parkinson’s disease. Clinical Neuropharmacology 20: 204–209PubMedCrossRefGoogle Scholar
  21. 21.
    The French Clozapine Parkinson Study Group (1999) Clozapine in drug-induced psychosis in Parkinson’s disease. The Lancet 353: 2041–2042CrossRefGoogle Scholar
  22. 22.
    Auzou P, Özsancak C, Hannequin D, Moore N, Augustin P (1996) Clozapine for the treatment of psychosis in Parkinson’s disease: a review. Acta Neurol Scand 94: 329–336PubMedCrossRefGoogle Scholar
  23. 23.
    Graas M, Diederich N (1997) Exogene Psychosen beim Morbus Parkinson und ihre Behandlung mit Clozapin. Nervenheilkunde 16: 122–131Google Scholar
  24. 24.
    Richard IH, Nutt J (2000) Worsening of motor function in Parkinson’s disease. Neurology 55: 748–749PubMedCrossRefGoogle Scholar
  25. 25.
    Goetz CG, Blasucci LM, Leurgans S, Pappert EJ (2000) Olanzapine and Clozapine. Neurology 55: 789–794PubMedCrossRefGoogle Scholar
  26. 26.
    Friedman JH, Goldstein S, Jacques C (1998) Substituting Clozapine for olanzapine. Clinical Neuropharmacology 21: 285–288PubMedGoogle Scholar
  27. 27.
    Molho ES, Factor SA (1999) Worsening of motor features of parkinsonism with olanzapine. Movement Disorders 14: 1014–1016PubMedCrossRefGoogle Scholar
  28. 28.
    Wolters EC, Janson ENH, Tuynman-Qua HG, Bergmans PLM (1996) Olanzapine in the treatment of dopaminomitic psychosis in patients with Parkinson’s disease. Neurology 47: 1085–1087PubMedCrossRefGoogle Scholar
  29. 29.
    Aarsland D, Larsen JP, Lim NG, Tandberg E (1999) Olanzapine for psychosis in patients with Parkinson’s disease with and without dementia. Neuropsychiatry Clin 11: 392–394Google Scholar
  30. 30.
    Menza MMA, Palermo B, Mark M (1999) Quetiapine as an alternative to Clozapine. Annals of Clinical Psychiatry 11: 141–144PubMedGoogle Scholar
  31. 31a.
    Fernandez HH, Friedman JH, Jaques C, Rosenfeld M (1999) Quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Movement Disorders 14: 484–487PubMedCrossRefGoogle Scholar
  32. 31b.
    Friedman JH, Fernandez HH, Jacques C, Rosenfeld M (1999) Quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Neurology 52(6) suppl 2: A215Google Scholar
  33. 32.
    Targum SD, Abbott JL (2000) Efficacy of quetiapine in Parkinson’s patients with psychosis. Journal of Clin Psychopharmacology 20: 54–60CrossRefGoogle Scholar
  34. 33.
    Dewey RB, O’Suilleabhain PE (2000) Treatment of drug-induced psychosis with quetiapine and Clozapine in Parkinson’s disease. Neurology 55: 1753–1754PubMedCrossRefGoogle Scholar
  35. 34.
    Weiner WJ, Minagar A, Shulman LM (2000) Quetiapine for L-dopa-induced psychosis in PD. Neurology 55: 899Google Scholar
  36. 35.
    Fernandez HH (2000) Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Movement Disorders 15: 579–586PubMedCrossRefGoogle Scholar
  37. 36.
    Mohr E, Mendis T, Hildebrand K, De Deyn PP (2000) Risperidone in the treatment of dopamine-induced psychosis in Parkinson’s disease: an open pilot trial. Movement Disorders 15: 1230–1237PubMedCrossRefGoogle Scholar
  38. 37.
    Ling ZD, Stebbins GT, Carvey PM (1997) Risperidone in levodopa-induced psychosis. Movement Disorders 12: 610–612CrossRefGoogle Scholar
  39. 38.
    Leopold NA (2000) Risperidone treatment of drug-related psychosis in patients with parkinsonism. Movement Disorders 15: 301–304PubMedCrossRefGoogle Scholar
  40. 39.
    Rich SS, Friedman JH, Ott BR (1995) Risperidone versus Clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. Clin Psychiatry 56: 556–559Google Scholar
  41. 40.
    Friedman JH, Ikeguchi K, Kuroda A (1996) Comments and Reply on Ikeguchi and Kuroda: mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Clin Neurosci 246: 106–107Google Scholar
  42. 41.
    Barbato L, Monge A, Stocchi F, Nordera G (1996) Melperone in the treatment of iatrogenic psychosis in Parkinson’s disease. Functional Neurology 11: 4Google Scholar
  43. 42.
    McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, Perry EK (2000) Rivastigmine in the treatment of dementia with lewy bodies: preliminary findings from an open trial. Int J Geriat Psychiatry 15: 387–392CrossRefGoogle Scholar
  44. 43.
    Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, Warren K, Jeste DV (2000) Better cognitive and Psychopathologic response to donepezil in patients prospectively diagnosed as dementia with lewy bodies: a preliminary study. Int J Geriatr Psychiatry 15: 794–802PubMedCrossRefGoogle Scholar
  45. 44.
    Moskovitz C, Moses H, Klawans HL (1978) Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 135: 669–675PubMedGoogle Scholar
  46. 45.
    Sharf B, Moskovitz C, Lupton MD et al. (1978) Dream phenomena induced by chronic levodopa therapy. J Neural Transm 43: 143–151PubMedCrossRefGoogle Scholar
  47. 46.
    Turner TH, Cookson JC, Wass JA, Drury PL, Price PA, Besser GM (1984) Psychotic reactions during treatment of pituitary tumours with dopamine agonists. Br Med J 289: 1101–1103CrossRefGoogle Scholar
  48. 47.
    Aarsland D, Larsen JP, Cummings JL, Laake K (1999) Prevalence and clinical correlates of psychotic symptoms in Parkinson disease. A community-based study. Arch Neurol 56: 595–601PubMedCrossRefGoogle Scholar
  49. 48.
    Litvan I, Maclntyre A, Goetz CG, Wenning GK, Jellinger K (1998) Accuracy of the clinical diagnosis of Lewy body disease, Parkinson’s disease and dementia with Lewy bodies: a clinic pathologic study. Arch Neurol 55: 969–978PubMedCrossRefGoogle Scholar
  50. 49.
    Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in Parkinsonism with Clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci 235: 60–64PubMedCrossRefGoogle Scholar
  51. 50.
    Rinne UK (1982) Brain neurotransmitter receptors in Parkinson’s disease. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth Scientific, Boston, pp 59–74Google Scholar
  52. 51.
    Sanchez-Ramos JR, Ortoll R, Paulson GW (1996) Visual hallucinations associated with Parkinson’s disease. Arch Neurol 53: 1265–1268PubMedCrossRefGoogle Scholar
  53. 52.
    Glennon RA, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35: 2505–2511PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • S. Bittkau

There are no affiliations available

Personalised recommendations